A5031464448- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- Pregnancy and Medication Impact
- HIV-related health complications and treatments
- Breastfeeding Practices and Influences
- HIV/AIDS drug development and treatment
- Reproductive Health and Contraception
- HIV Research and Treatment
- Global Maternal and Child Health
- Maternal Mental Health During Pregnancy and Postpartum
- Global Public Health Policies and Epidemiology
- Medication Adherence and Compliance
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Pharmaceutical studies and practices
- Folate and B Vitamins Research
- Cerebrovascular and Carotid Artery Diseases
- Sex work and related issues
- Healthcare Decision-Making and Restraints
- Obesity and Health Practices
- Problem and Project Based Learning
- Psychiatric care and mental health services
- Education Systems and Policy
- Biomedical and Engineering Education
- Innovations in Medical Education
B.C. Women's Hospital & Health Centre
2017-2023
Women's Health Research Institute
2017-2023
University of British Columbia
2015-2023
Children's & Women's Health Centre of British Columbia
2023
Provincial Health Services Authority
2022
University of British Columbia Hospital
2004-2022
AIDS Vancouver
2017-2018
British Columbia Centre of Excellence for Women's Health
2017-2018
Women's Hospital
2015
Simon Fraser University
2013
Dengue fever is an acute viral disease, which usually presents as a mild febrile illness. Patients with severe disease present dengue haemorrhagic or toxic shock syndrome. Rarely, it abdominal symptoms mimicking appendicitis. We case of male patient presenting right iliac fossa pain and suspected appendicitis that was later diagnosed following negative appendicectomy.A 13-year old presented fever, localized right-sided vomiting. Abdominal ultrasound not helpful appendicectomy performed due...
To describe the impact of initiating raltegravir (RAL)-containing combination antiretroviral therapy (cART) regimens on HIV viral load (VL) in pregnant women who have high or suboptimal VL suppression late pregnancy.HIV-infected started RAL-containing cART after 28 weeks' gestation from 2007 to 2013 were identified two university hospital centres.Eleven HIV-infected RAL at a median gestational age 35.7 weeks (range 31.1 38.0 weeks). Indications for initiation presentation pregnancy (n=4) and...
OBJECTIVE: To assess the stability of human immunodeficiency virus (HIV) viral load suppression within 1 month before birth in pregnant women receiving antenatal combination antiretroviral therapy (CART). METHODS: This is a retrospective cohort study Canadian provincial perinatal HIV database from 1997 to 2015. Inclusion criteria were live and CART received for at least 4 weeks. Viral rebound, defined as greater than 50 copies/mL (or 400 1997–1998) measured delivery, was identified who had...
Abstract Background While treatment guidelines for HIV in adults have evolved rapidly with the advent of new antiretroviral (ARV) treatment, those prevention vertical transmission pregnancy more slowly due to safety and efficacy concerns. Here we describe Canadian prescribing patterns ARV treatments during compare them perinatal United States Department Health Human Services ( HHS ), that are commonly used Canada include recommendations newly commercialized therapies. Methods The Perinatal...
We wished to evaluate the efficacy, safety, and acceptability of cabergoline for lactation inhibition in women who live with HIV. In this multicenter prospective observational study, was offered as a single oral dose 1 mg within first 48 h postpartum. Women were recruited if they delivered infant after 35 weeks gestational age. Participants filled out questionnaire regarding symptoms adverse effects on day 2 14 On 14, also completed about their satisfaction treatment. Prolactin serum level...
Introduction. A pilot project was established at the Cross Cancer Institute pharmacy to assess feasibility of implementing a patient callback program determine which patients would benefit from and impact service have on workload department. Program description/development/implementation/evaluation. student conducted over 14-week time period. Four categories were selected for inclusion in pilot. The approached medication pick-up receive verbal permission be included program. standardized...
Abstract Background Ritonavir‐boosted darunavir (DRV/r) is a preferred protease inhibitor in pregnant women living with HIV. Current practice at British Columbia's referral centre (the Oak Tree Clinic) to dose DRV/r as 800/100 mg daily throughout pregnancy, although some guidelines recommend 600/100 twice due altered pharmacokinetics once‐daily dosing. Objectives We describe the effect of on viral suppression, vertical transmission, adverse drug effects and adherence Methods This was...
Rates of unintended pregnancy are higher in women living with HIV than those without HIV. The World Health Organization and the Canadian Pregnancy Planning Guidelines recommend preventing pregnancies offering contraception counselling to reduce rate perinatal transmission worldwide. No studies have assessed post-partum (PP) use Canada.We conducted a retrospective chart review including all followed by Oak Tree Clinic who had live birth between 1 January 2014 15 September 2019. main objective...
( Obstet Gynecol . 2017;130(3):497–501) The administration of intrapartum intravenous (IV) zidovudine in combination with antenatal and neonatal was the first antiretroviral regimen recommended for pregnant women by all guidelines. However, advent therapy (CART), as well finding that an HIV viral load <1000 copies mL at delivery who receive IV may carry increased risk vertical transmission compared controls, guidelines have since changed.